Golimumab is contraindicated in individuals with hypersensitivity to the drug, prior use of TNF-α inhibitors, active or recurrent infections, a history of malignancies, or concurrent treatment with other immunosuppressive agents [91]. This evidence concerns the gene TNF and infection.